HSCS — HeartSciences Income Statement
0.000.00%
Last trade - 00:00- $3.89m
- $3.82m
- $0.02m
- 22
- 13
- 67
- 26
Annual income statement for HeartSciences, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.064 | 0.026 | 0.014 | 0.005 | 0.019 |
| Cost of Revenue | |||||
| Gross Profit | 0.018 | 0.015 | 0.006 | 0.002 | 0.013 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.87 | 2.34 | 4.47 | 6.12 | 6.32 |
| Operating Profit | -3.81 | -2.32 | -4.46 | -6.11 | -6.31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.81 | -2.45 | -4.83 | -6.35 | -6.61 |
| Net Income After Taxes | -3.81 | -2.45 | -4.83 | -6.35 | -6.61 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.81 | -2.45 | -4.83 | -6.35 | -6.61 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -3.81 | -2.45 | -4.83 | -6.35 | -6.61 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.475 | -0.336 | -0.617 | -0.799 | -18.7 |
| Dividends per Share |